Ovoca Bio said staffing issues at an Australian CRO caused the Irish biotech to suspend a phase 2 trial of its novel treatment for women with hypoactive sexual desire disorder.
Dublin, Ireland, 7 March, 2022 - The Board of Ovoca Bio, an international biopharmaceutical company focusing on women's health, today issues a statement in response to events in Ukraine and Russia.
Second Price Monitoring Extn
Russian Marketing Authorisation for Orenetide
Market Place
Share Share
Share Share
